Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Outlook Therapeutics Inc. OTLK

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.


Recent & Breaking News (NDAQ:OTLK)

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

GlobeNewswire 5 days ago

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

GlobeNewswire 6 days ago

Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

GlobeNewswire August 30, 2022

Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD

GlobeNewswire August 15, 2022

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

GlobeNewswire August 10, 2022

Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

GlobeNewswire August 4, 2022

Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

GlobeNewswire July 5, 2022

Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010

GlobeNewswire June 14, 2022

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire May 31, 2022

Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

GlobeNewswire May 13, 2022

Outlook Therapeutics to Participate in Retina World Congress 2022

GlobeNewswire May 10, 2022

Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight

GlobeNewswire May 9, 2022

BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

GlobeNewswire April 22, 2022

Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit

GlobeNewswire April 5, 2022

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire March 31, 2022

Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access

GlobeNewswire March 3, 2022

Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress

GlobeNewswire February 24, 2022

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update

GlobeNewswire February 14, 2022